Evidence map›Paper›PMID 42139359›Full record

ArticleScience advances2026

Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses.

Wilson W Ng, Jamie Sugrue, Jaime S Rosa Duque, Vincent Rouilly, Vincent Bondet, Chloe Albert, Florian Dubois, Marie Robert, Daniel Leung, Peter Chung and 19 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Wilson W NgCentre for Immunology and Infection, Hong Kong SAR, China.ORCID 0000-0003-1359-7398
Jamie SugrueTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0001-7270-3838
Jaime S Rosa DuqueDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-5292-5510
Vincent RouillyCentre for Immunology and Infection, Hong Kong SAR, China.
Vincent BondetTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-6534-0984
Chloe AlbertTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-5914-3554
Florian DuboisTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-7034-0866
Marie RobertTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-1374-6210
Daniel LeungDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-9360-6233
Peter ChungCentre for Immunology and Infection, Hong Kong SAR, China.
Theodora H Y LukCentre for Immunology and Infection, Hong Kong SAR, China.
Ashley B S LiCentre for Immunology and Infection, Hong Kong SAR, China.
Rex L HungCentre for Immunology and Infection, Hong Kong SAR, China.ORCID 0009-0006-7239-3052
Etienne VillainTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0001-9907-9094
Melanie BriardTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0001-6479-408X
Garrick YipCentre for Immunology and Infection, Hong Kong SAR, China.
Milieu Intérieur Consortium
Daniel LarocqueR&D, Sanofi Vaccines Business Unit, Marcy L'Etoile, France.ORCID 0000-0002-2514-3687
Etienne PatinHuman Evolutionary Genetics Unit, Institut Pasteur, Université Paris Cité, CNRS UMR2000, Paris, France.ORCID 0000-0002-9911-4459
Lluis Quintana-MurciHuman Evolutionary Genetics Unit, Institut Pasteur, Université Paris Cité, CNRS UMR2000, Paris, France.ORCID 0000-0003-2429-6320
Gabriel M LeungSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Michael Y NiSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-1217-5858
Pedro GoncalvesInnate Immunity Unit, Institut Pasteur, Université Paris Cité, INSERM U1223, Paris, France.ORCID 0000-0002-4127-1152
Olivier SchwartzVirus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-0729-1475
James Di SantoCentre for Immunology and Infection, Hong Kong SAR, China.ORCID 0000-0002-7146-1862
Roberto BruzzoneCentre for Immunology and Infection, Hong Kong SAR, China.ORCID 0000-0003-4373-1447
Malik PeirisCentre for Immunology and Infection, Hong Kong SAR, China.ORCID 0000-0001-8217-5995
Yu Lung LauDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-4780-0289
Darragh DuffyCentre for Immunology and Infection, Hong Kong SAR, China.ORCID 0000-0002-8875-2308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biological predictors of variable vaccine responses are lacking. We hypothesized that variability in prevaccine innate immune responses, specifically for type I interferons (IFN-I), is predictive of postvaccine antigen-specific responses. To test this, we assessed prevaccine immune responses at protein and transcriptomic levels following whole blood stimulation with Toll-like receptor (TLR) viral agonists in healthy adolescents and adults. Four weeks after the second vaccine dose, with either the BNT162b2 mRNA or CoronaVac inactivated virus vaccine, we assessed antigen-specific T cell cytokine responses and plasma antibody levels. BNT162b2 vaccinees had increased production of the antigen-specific T cell cytokines interleukin-2 (IL-2), interferon-γ, and IL-21 after severe acute respiratory syndrome coronavirus 2 spike stimulation, as well as increased antibody levels and serum pseudo-neutralization compared with CoronaVac recipients. In direct support of our hypothesis, we find that prevaccine poly(I:C) (polyinosine-polycytidylic acid; TLR3 viral agonist) IFN-I responses were significantly associated with the postvaccine T cell cytokine responses. In an independent cohort of 990 healthy donors, we confirmed the significant association between poly(I:C)-induced IFN-α and spike-induced cytokines in mRNA vaccine recipients. We further confirmed this specific association in a cohort of healthy Europeans and identified a common genetic polymorphism in TLR3 that affects IFN-I induction and subsequent vaccine-specific T cell responses. This study shows that preexisting innate immune variability can predict the effectiveness of vaccine responses and identifies pathways relevant to mRNA vaccination. Targeting the specific innate immune pathway relevant for a vaccine may provide a new approach for tailoring vaccines to different populations.

Indexed as

Interferon Type IToll-Like Receptor 3AdolescentAdultAntibodies, ViralBNT162 VaccineCytokinesFemaleHumansImmunity, InnateMaleSARS-CoV-2Signal TransductionT-LymphocytesToll-Like Receptor AgonistsAntibodies, ViralBNT162 VaccineCytokinesInterferon Type ITLR3 protein, humanToll-Like Receptor 3Toll-Like Receptor Agonists

Identifiers

PMID42139359
PMCPMC13178536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.